Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ARTL

ARTL - Artelo Biosciences Inc Stock Price, Fair Value and News

$1.69-0.11 (-6.11%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

ARTL Price Action

Last 7 days

1.8%

Last 30 days

-43.7%

Last 90 days

-61.1%

Trailing 12 Months

-73.9%

ARTL RSI Chart

ARTL Valuation

Market Cap

3.4M

Price/Earnings (Trailing)

-0.27

Price/Sales (Trailing)

1.8K

Price/Free Cashflow

-0.42

ARTL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ARTL Fundamentals

ARTL Revenue

Revenue (TTM)

2.0K

Rev. Growth (Yr)

114.29%

Rev. Growth (Qtr)

400%

ARTL Earnings

Earnings (TTM)

-12.5M

Earnings Growth (Yr)

-175.62%

Earnings Growth (Qtr)

3.14%

ARTL Profitability

Return on Equity

2.0K%

Return on Assets

-292.73%

Free Cashflow Yield

-239.65%

ARTL Investor Care

Shares Dilution (1Y)

275.27%

Diluted EPS (TTM)

-20.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20240000
20223.0K4.0K3.0K2.0K
2021699.1K559.7K420.3K141.4K
20201.3M1.2M978.0K838.6K
2019735.0K852.6K1.2M1.3M
2018331.9K491.8K585.1K645.0K
201775.4K98.7K121.9K220.1K
20160028.9K52.2K
Get all data in R, Python etc through our Historical Stock Data APIs

About Artelo Biosciences Inc

ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
 CEO
 WEBSITEartelobio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES5

Artelo Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Artelo Biosciences Inc? What does ARTL stand for in stocks?

ARTL is the stock ticker symbol of Artelo Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Artelo Biosciences Inc (ARTL)?

As of Wed Dec 03 2025, market cap of Artelo Biosciences Inc is 3.41 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARTL stock?

You can check ARTL's fair value in chart for subscribers.

Is Artelo Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether ARTL is over valued or under valued. Whether Artelo Biosciences Inc is cheap or expensive depends on the assumptions which impact Artelo Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARTL.

What is Artelo Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, ARTL's PE ratio (Price to Earnings) is -0.27 and Price to Sales (PS) ratio is 1.82 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARTL PE ratio will change depending on the future growth rate expectations of investors.